Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Ordu C., Pilanci K. N., Avci N., YILDIZ İ., Alco G., Demirhan O., ...Daha Fazla

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.20, sa.2, ss.147-152, 2016 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5114/wo.2016.60069
  • Dergi Adı: WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.147-152
  • Anahtar Kelimeler: metastatic renal cell carcinoma, prognostic factors, dosing schedule, sunitinib toxicity, PHASE-II TRIAL, INTERFERON-ALPHA, CLINICAL-TRIALS, CARCINOMA, HYPOTHYROIDISM, SURVIVAL, HYPERTENSION, INHIBITOR, THERAPIES, BIOMARKER
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Aim of the study: Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug.